FDA granted approval Tuesday to Epic Pharma for a generic ANDA filing, adding another formulation of metformin hydrochloride to the schedule of available diabetes treatments. Although the drug is a generic, the expansion of marketing options may heighten competitive pressure on branded formulations of the widely prescribed antidiabetic agent.